Drug Approval | August 17, 2021
Caplin Point Lab's subsidiary receives nod from Brazil's ANVISA for sterile injectable manufacturing site
The approval allows it to market its products in the country
The approval allows it to market its products in the country
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
The deal, backed by healthcare investor ARCHIMED, signals a major push to accelerate connected, patient-centered cardiac care worldwide
Patalganga plant received zero observation from USFDA earlier
Backed by ARCHIMED, the deal strengthens connected cardiac diagnostics with integrated Holter, ABPM, and telemedicine solutions
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Stakeholders call for coordinated action on diagnostics, vaccines, and health system readiness as the monsoon season approaches
Outlines nine priority health tracks spanning TB research, digital health, early warning systems and regulatory cooperation
Subscribe To Our Newsletter & Stay Updated
